Publication Name	World Journal of Hepatology
Manuscript ID	13312
Country	China

Received	2014-08-16 20:44
Peer-Review Started	2014-08-17 21:43
To Make the First Decision	2014-09-16 10:44
Return for Revision	2014-09-18 16:56
Revised	2014-09-29 20:38
Second Decision	2014-10-29 18:06
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-10-29 19:01
Articles in Press	2014-10-29 19:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-12-05 17:21
Publish the Manuscript Online	2014-12-13 17:50

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out
Manuscript Source	Invited Manuscript
All Author List	Hong Sun, Man-Sheng Zhu, Wen-Rui Wu, Xiang-De Shi and Lei-Bo Xu
Funding Agency and Grant Number	Funding Agency Grant Number Special Research Foundation of the National Nature Science Foundation of China 81302143 Natural Science Foundation of Guangdong Province, China S2013040015045
Corresponding Author	Dr. Lei-Bo Xu, Department of Hepato-pancreato-biliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang Xi Lu, Guangzhou 510120, Guangdong Province, China. mdxuleibo@hotmail.com
Key Words	Hepatocellular carcinoma; Management; Molecularly targeted therapy; Anti-angiogenesis; Sorafenib
Core Tip	Hepatocellular carcinoma (HCC) is a devastating disease with a high mortality rate. For a long period of time, no effective treatment options are available for patients with advanced HCC. During the last decade, molecularly targeted therapies have been introduced into the treatment of advanced HCC. However, the efficacy and safety of molecularly targeted therapies remain controversial. In addition, primary or acquired drug resistance limits the activity of molecularly targeted agents, but the underlying mechanisms have not been fully understood. This concise review aims to provide an overview of anti-angiogenesis therapy in the treatment of HCC.
Publish Date	2014-12-13 17:50
Citation	Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835
URL	http://www.wjgnet.com/1948-5182/full/v6/i12/830.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i12.830

Full Article (PDF)	WJH-6-830.pdf
Full Article (Word)	WJH-6-830.doc
Manuscript File	13312-Review.docx
Answering Reviewers	13312-Answering reviewers.pdf
Copyright License Agreement	13312-Copyright assignment.pdf
Peer-review Report	13312-Peer review(s).pdf
Scientific Misconduct Check	13312-CrossCheck.jpg
Scientific Editor Work List	13312-Scientific editor work list.pdf